deltatrials
Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07230626

SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

A Randomized, Open-Label, Controlled, Multicenter Phase 3 Trial of SYS6002 Versus Chemotherapy of Physician's Choice in Recurrent or Metastatic Cervical Cancer After Platinum-containing Chemotherapy and Anti-PD-(L)1 Agent Therapy

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

Conditions Cervical Cancer
Interventions Investigator's Choice of Chemotherapy SYS6002
Updated 1 time since 2025 Last updated: Nov 13, 2025 Started: Nov 20, 2025 Primary completion: Jan 1, 2028 Completion: Jul 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07230626, this PHASE3 trial focuses on Cervical Cancer and remains actively recruiting participants. Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2025 – present · 7 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CSPC Megalith Biopharmaceutical Co.,Ltd.
Data source: CSPC Megalith Biopharmaceutical Co.,Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.